12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

APD515: Phase II started

Acacia began a double-blind, placebo-controlled, crossover, U.K. and Danish Phase II trial to evaluate 20 mg APD515 given 4 times...

Read the full 76 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >